Abeona Therapeutics Inc
ABEOHealthcare·Biotechnology·USA·Micro·NASD·Nov 12 • 3:59 PM ET
2.29-0.01 (-0.43%)
2026-11-13 13:03 CET
Market cap
$130.87M
Revenue, TTM
39.01 USD m
Net income, TTM
-62.53 USD m
Free cash flow, TTM
-66.35 USD m
EPS diluted, TTM
-1.11
Price
ABEO against its 20, 50 and 200-day averagesPatternshover a marker to name it
70.1% under the 52-week high of 7.65 on 11 Aug 2026. 52-week low 2.22 on 12 Nov 2026. Last 15 sessions, 113.1% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 1 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
ABEO52-week range, 1% of the way up
2.227.65
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
| Index | RUT |
|---|---|
| Employees | 226 |
| IPO | Sep 19, 1980 |
| Beta | 1.51 |
| ATR, 14d | 0.32 |
| Rel volume | 0.00 |
| Short float | 33.31% |
| Insider own | 11.33% |
| Inst own | 66.21% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $130.87M |
| Enterprise Value | 12.56M |
| Income | -62.53M |
| Sales | 39.01M |
| Book / share | 2.20 |
| Cash / share | 2.36 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | 0.00% |
| Employees | 226 |
| IPO | Sep 19, 1980 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 3.35 |
| Price / book | 1.04 |
| Price / cash | 0.97 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 0.32 |
| Quick Ratio | 5.52 |
| Current Ratio | 5.69 |
| Debt / equity | 0.13 |
| Long-term debt / equity | 0.03 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -1.11 |
|---|---|
| Earnings next year | -0.44 |
| Earnings next quarter | -0.23 |
| Earnings this year | -196.53% |
| Earnings next year | 54.87% |
| Earnings growth, 5 years | - |
| Past earnings growth | - - |
| Past sales growth | 60.26% -10.26% |
| Earnings vs last year | -172.49% |
| Sales vs last year | 9652.75% |
| Earnings vs last quarter | 12.71% |
| Sales vs last quarter | - |
| Earnings | Nov 09 BMO |
| Surprise | 54.10% -8.96% |
Ownership
| Insiders own | 11.33% |
|---|---|
| Insider trades | -5.30% |
| Institutions own | 66.21% |
| Institution trades | 0.75% |
| Return on assets | -31.03% |
| Return on equity | -42.09% |
| Return on capital | -48.35% |
| Gross Margin | 52.51% |
| Operating margin | -186.10% |
| Profit Margin | -160.30% |
| 20-day average | -43.21% |
| 50-day average | -53.06% |
| 200-day average | -57.78% |
Technical
| Shares out | 57.17M |
|---|---|
| Shares floating | 50.67M |
| Short / float | 33.31% |
| Short ratio | 10.06 |
| Short interest | 16.88M |
| 52-week high | 7.65 -70.1% |
| 52-week low | 2.22 +3.2% |
| Volatility | 18.17% 8.23% |
| Average range | 0.32 |
| Strength index | 14.18 |
| Market sensitivity | 1.51 |
| Relative volume | 0.00 |
| Avg Volume | 1.68M |
| Volume | 0 |
Performance
| Perf Week | -46.12% |
|---|---|
| Perf Month | -47.48% |
| Perf Quarter | -61.74% |
| Perf Half Y | -59.11% |
| Perf YTD | -56.55% |
| Perf Year | -53.64% |
| Perf 3Y | -44.01% |
| Perf 5Y | -89.99% |
| Perf 10Y | -98.58% |
| Recommendation | 1.00 |
| Target Price | 15.56 |
| Prev Close | 2.29 |
| Price | 2.29 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 17, 2026 | Initiated | Roth Capital | Buy | $17 | +642.4% |
| Jun 02, 2025 | Resumed | Oppenheimer | Outperform | $19 | +729.7% |
| Mar 05, 2025 | Initiated | Oppenheimer | Outperform | $16 | +598.7% |
| Jul 03, 2024 | Initiated | H.C. Wainwright | Buy | $15 | +555.0% |
| May 30, 2024 | Initiated | Stifel | Buy | $21 | +817.0% |
| Nov 11, 2020 | Upgrade | Cantor Fitzgerald | Neutral → Overweight | $4 | +74.7% |
| Sep 18, 2020 | Initiated | B. Riley FBR | Buy | $5 | +118.3% |
| Feb 10, 2020 | Initiated | SVB Leerink | Outperform | $6 | +162.0% |
| Dec 10, 2019 | Resumed | Cantor Fitzgerald | Neutral | $2 → $4 | +74.7% |
| Aug 15, 2019 | Downgrade | Maxim Group | Buy → Hold |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| KRYS | Krystal Biotech Inc | 9.06B |
| VCEL | Vericel Corp | 2.93B |
| RGNX | Regenxbio Inc | 538.23M |
| RCKT | Rocket Pharmaceuticals Inc | 259.07M |
| CUVL | Clinuvel Pharmaceuticals Ltd ADR | 254.97M |
| SRPT | Sarepta Therapeutics Inc | 1.74B |
| RARE | Ultragenyx Pharmaceutical Inc | 1.66B |
| MGTX | MeiraGTx Holdings plc | 844.22M |
| RCEL | AVITA Medical Inc | 401.41M |
| QURE | uniQure NV | 1.72B |
Insider trading
latest 14 of 68| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | Chief Executive Officer | Sep 29 '26 | Sale | 5.16 | 19,608 | 101,091 | 1,286,500 | Sep 29 09:48 PM |
| Vazzano Joseph Walter | Chief Financial Officer | Sep 29 '26 | Sale | 5.16 | 9,191 | 47,385 | 482,888 | Sep 29 09:48 PM |
| O'Malley Brendan M. | SVP, Chief Legal Officer | Sep 29 '26 | Sale | 5.16 | 6,727 | 34,682 | 421,226 | Sep 29 09:48 PM |
| Vasanthavada Madhav | Chief Commercial Officer | Sep 29 '26 | Sale | 5.16 | 4,902 | 25,273 | 285,721 | Sep 29 09:47 PM |
| Vazzano Joseph Walter | Officer | Sep 29 '26 | Proposed Sale | 5.16 | 9,191 | 47,385 | Sep 29 04:54 PM | |
| Seshadri Vishwas | Officer | Sep 29 '26 | Proposed Sale | 5.16 | 19,608 | 101,091 | Sep 29 04:48 PM | |
| Vasanthavada Madhav | Officer | Sep 29 '26 | Proposed Sale | 5.16 | 4,902 | 25,273 | Sep 29 04:47 PM | |
| O'Malley Brendan M. | Officer | Sep 29 '26 | Proposed Sale | 5.16 | 6,727 | 34,682 | Sep 29 04:46 PM | |
| Alvino Mark | Director | Sep 01 '26 | Sale | 5.86 | 15,000 | 87,966 | 62,065 | Sep 01 05:48 PM |
| Alvino Mark | Director | Sep 01 '26 | Proposed Sale | 5.86 | 15,000 | 87,966 | Sep 01 04:05 PM | |
| Vazzano Joseph Walter | Chief Financial Officer | Jul 21 '26 | Sale | 6.53 | 1,478 | 9,651 | 492,079 | Jul 22 04:30 PM |
| Vazzano Joseph Walter | Chief Financial Officer | Jul 09 '26 | Sale | 6.96 | 24,880 | 173,257 | 493,557 | Jul 09 07:24 PM |
| Seshadri Vishwas | Chief Executive Officer | Jul 09 '26 | Sale | 6.96 | 67,971 | 473,330 | 1,306,108 | Jul 09 07:22 PM |
| O'Malley Brendan M. | SVP, Chief Legal Officer | Jul 09 '26 | Sale | 6.96 | 12,050 | 83,913 | 427,953 | Jul 09 07:20 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| ITOT | iShares Core S&P Total U.S. Stock Market ETF | AUM: 96.50B |
| VTWV | Vanguard Russell 2000 Value Index ETF | AUM: 1.29B |
| EES | WisdomTree U.S. SmallCap Fund | AUM: 690.24M |
| GSSC | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | AUM: 1.07B |
News
latest 14 of 200- AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning (BioPharma Dive) -6.31%
- Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
- Abeona Beats On EPS But Misses Revenue By 25% As The ZEVASKYN Ramp Slows And The Company Adds An EoE Asset (Earnings Whispers) -40.24%
- Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press)
- Abeona Therapeutics Reports Third Quarter 2026 Financial Results and ZEVASKYN Commercial Progress (GlobeNewswire)
- Abeona Therapeutics Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement (GlobeNewswire)
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
- ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells (Stocktwits)
- Abeona Therapeutics Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN (GlobeNewswire)
- Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ... (GuruFocus.com)
Quarterly earnings
2026Q3 EPS -0.080 beat -0.174, from -0.100 a year earlier. Sales 13.49 missed 14.82, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-09 08:30 | -0.080 | -0.174 | -0.080 | 13.49 | 14.82 | EPS -54.1% · sales -9.0% | vs 2025Q3, year-ago quarter · EPS -20.0% · sales - | 7 EPS · 8 sales | - |
| 2026Q2ended 2026-06-30 | 2026-08-13 08:30 | -0.350 | -0.232 | -0.354 | 11.38 | 12.24 | EPS +51.1% · sales -7.0% | vs 2025Q2, year-ago quarter · EPS -120.5% · sales +2745.0% | 6 EPS · 7 sales | Open -18.36% vs SPY +0.31%. Close -14.95% vs SPY +0.70% |
| 2026Q1ended 2026-03-31 | 2026-05-13 08:30 | -0.300 | -0.335 | -0.302 | 8.72 | 4.57 | EPS -10.4% · sales +90.7% | vs 2025Q1, year-ago quarter · EPS +25.0% · sales - | 6 EPS · 7 sales | Open +2.29% vs SPY +0.04%. Close +0.53% vs SPY +0.56% |
| 2025Q4ended 2025-12-31 | 2026-03-17 08:30 | -0.360 | -0.352 | -0.372 | 4.98 | 4.42 | EPS +2.3% · sales +12.6% | vs 2024Q4, year-ago quarter · EPS -172.0% · sales - | 5 EPS · 6 sales | Open -3.43% vs SPY +0.50%. Close -3.84% vs SPY +0.26% |
| 2025Q3ended 2025-09-30 | 2025-11-12 08:30 | -0.100 | -0.282 | -0.095 | 0.00 | 5.19 | EPS -64.5% · sales -100.0% | vs 2024Q3, year-ago quarter · EPS -84.1% · sales - | 5 EPS · 6 sales | Open +8.63% vs SPY +0.26%. Close +18.47% vs SPY +0.06% |
| 2025Q2ended 2025-06-30 | 2025-08-14 08:30 | 1.710 | -0.390 | 1.706 | 0.40 | 0.00 | EPS -538.5% · sales - | vs 2024Q2, year-ago quarter · EPS -757.7% · sales - | 5 | Open +4.42% vs SPY -0.33%. Close +10.21% vs SPY +0.01% |
| 2025Q1ended 2025-03-31 | 2025-05-15 08:30 | -0.240 | -0.358 | -0.242 | 0.00 | 0.00 | EPS -33.0% · sales - | vs 2024Q1, year-ago quarter · EPS -79.3% · sales - | 5 | Open -0.56% vs SPY -0.35%. Close +7.42% vs SPY +0.49% |
| 2024Q4ended 2024-12-31 | 2025-03-20 08:30 | 0.500 | -0.348 | -0.204 | 0.00 | 0.10 | EPS -243.7% · sales -100.0% | vs 2023Q4, year-ago quarter · EPS -184.7% · sales - | 5 | Open +3.08% vs SPY -0.67%. Close -1.15% vs SPY -0.29% |
| 2024Q3ended 2024-09-30 | 2024-11-14 08:30 | -0.630 | -0.393 | -0.630 | 0.00 | 0.10 | EPS +60.5% · sales -100.0% | vs 2023Q3, year-ago quarter · EPS +31.3% · sales - | 4 EPS · 5 sales | Open +3.28% vs SPY +0.02%. Close -2.46% vs SPY -0.64% |
| 2024Q2ended 2024-06-30 | 2024-08-12 08:30 | -0.260 | -0.342 | -0.263 | 0.00 | 0.10 | EPS -24.0% · sales -100.0% | vs 2023Q2, year-ago quarter · EPS -71.7% · sales -100.0% | 5 | Open +1.81% vs SPY +0.23%. Close +11.99% vs SPY +0.05% |
| 2024Q1ended 2024-03-31 | 2024-05-15 08:30 | -1.160 | -0.513 | -1.156 | 0.00 | 0.17 | EPS +126.0% · sales -100.0% | vs 2023Q1, year-ago quarter · EPS +114.8% · sales - | 3 | Open +0.95% vs SPY +0.48%. Close +12.14% vs SPY +1.24% |
| 2023Q4ended 2023-12-31 | 2024-03-18 08:30 | -0.590 | -0.470 | -0.649 | 0.00 | 0.00 | EPS +25.5% · sales - | vs 2022Q4, year-ago quarter · EPS +826.2% · sales -100.0% | 4 EPS · 3 sales | Open -8.46% vs SPY +0.82%. Close -19.00% vs SPY +0.59% |
| 2023Q3ended 2023-09-30 | 2023-11-13 08:30 | -0.480 | -0.533 | -0.477 | 0.00 | 0.00 | EPS -10.0% · sales - | vs 2022Q3, year-ago quarter · EPS -67.6% · sales - | 3 | - |
| 2023Q2ended 2023-06-30 | 2023-08-08 08:30 | -0.920 | -0.673 | -0.924 | 3.50 | 0.00 | EPS +36.6% · sales - | vs 2022Q2, year-ago quarter · EPS -55.8% · sales +250.0% | 3 | - |
| 2023Q1ended 2023-03-31 | 2023-05-11 08:30 | -0.540 | -0.610 | -0.539 | 0.00 | 0.00 | EPS -11.5% · sales - | vs 2022Q1, year-ago quarter · EPS -84.6% · sales -100.0% | 2 EPS · 3 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-29 08:30 | -0.064 | -0.750 | -0.064 | 0.07 | 1.00 | EPS -91.5% · sales -93.2% | vs 2021Q4, year-ago quarter · EPS -99.4% · sales -97.7% | 1 EPS · 2 sales | - |
Annual earnings
2025FY EPS 1.010 missed 1.145, from -1.550 a year earlier. Sales 5.82 beat 4.82, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 1.747 | - | - | 328.42 | 1.31 |
| 2029FYestimate | - | 1.133 | - | - | 281.69 | 2.02 |
| 2028FYestimate | - | 0.233 | - | - | 188.68 | 9.85 |
| 2027FYestimate | - | -0.440 | - | - | 102.44 | - |
| 2026FYestimate | - | -0.975 | - | - | 47.01 | - |
| 2025FY | 1.010 | 1.145 | 1.010 | 5.82 | 4.82 | 5.22 |
| 2024FY | -1.550 | -1.723 | -1.553 | 0.00 | 0.10 | - |
| 2023FY | -2.530 | -2.230 | -2.535 | 3.50 | 3.63 | - |
| 2022FY | -5.530 | -3.915 | -5.531 | 1.41 | 2.32 | - |
| 2021FY | -21.500 | -13.917 | -21.570 | 3.00 | 0.00 | - |
| 2020FY | -22.750 | -20.583 | -22.726 | 10.00 | 12.37 | - |
| 2019FY | -37.750 | -37.844 | -37.873 | 0.00 | 0.00 | - |
| 2018FY | -29.750 | -29.311 | -29.809 | 3.02 | 5.87 | - |
| 2017FY | -16.500 | -15.178 | -16.500 | 0.84 | 0.87 | - |
| 2016FY | -16.000 | -14.750 | -16.000 | 0.89 | 0.83 | - |
| 2015FY | -13.250 | -12.000 | -13.250 | 1.00 | 1.11 | - |
| 2014FY | -381.5 | - | - | 0.91 | - | - |
| 2013FY | 75.000 | - | 75.000 | 2.04 | - | 0.03 |
| 2012FY | -650 | - | -650 | 4.40 | - | - |
| 2011FY | -275 | -412.5 | -275 | 1.85 | 8.00 | - |
Quarterly results
2026Q3 revenue 13.49, from 0.00 a year earlier. Operating margin -96.4%
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -0.98 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-11 | -0.98 | -2.4% |
| 2026Q4 | E | per share | 2026-11-11 | -0.23 | -1.2% |
| 2026FY | R | per share | 2026-11-11 | -0.98 | -2.4% |
| 2026Q4 | R | per share | 2026-11-11 | -0.23 | -1.2% |
| 2026FY | S | per share | 2026-11-11 | 47.01 | -1.1% |
| 2026Q4 | S | per share | 2026-11-11 | 13.09 | -3.2% |
| 2026Q3 | E | per share | 2026-11-04 | -0.17 | 0.0% |
| 2026Q3 | R | per share | 2026-11-04 | -0.17 | 0.0% |
| 2026Q3 | S | per share | 2026-11-04 | 14.82 | 0.0% |
| 2026Q2 | E | per share | 2026-08-01 | -0.23 | 0.0% |
| 2026Q2 | R | per share | 2026-08-01 | -0.23 | 0.0% |
| 2026Q2 | S | per share | 2026-07-27 | 12.24 | 0.0% |
| 2026Q1 | E | per share | 2026-03-18 | -0.34 | -2.0% |
| 2026Q1 | R | per share | 2026-03-18 | -0.34 | -2.0% |
| 2026Q1 | S | per share | 2026-03-18 | 4.57 | -1.1% |
| 2025FY | E | per share | 2026-03-09 | 1.15 | +0.1% |
| 2025Q4 | E | per share | 2026-03-09 | -0.35 | -0.6% |
| 2025FY | R | per share | 2026-03-09 | 1.15 | +0.1% |
| 2025Q4 | R | per share | 2026-03-09 | -0.35 | -0.6% |
| 2025FY | S | per share | 2026-03-09 | 4.82 | +0.1% |
| 2025Q4 | S | per share | 2026-03-09 | 4.42 | +0.1% |
| 2025Q3 | E | per share | 2025-10-29 | -0.28 | 0.0% |
| 2025Q3 | R | per share | 2025-10-29 | -0.28 | 0.0% |
| 2025Q3 | S | per share | 2025-10-29 | 5.19 | 0.0% |
| 2025Q2 | E | per share | 2025-07-30 | -0.39 | 0.0% |
| 2025Q2 | R | per share | 2025-07-30 | -0.39 | 0.0% |
| 2025Q2 | S | per share | 2025-06-03 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-28 | -0.36 | -2.7% |
| 2025Q1 | R | per share | 2025-04-28 | -0.36 | -2.7% |
| 2025Q1 | S | per share | 2025-04-07 | 0.00 | - |
| 2024FY | E | per share | 2025-03-04 | -1.72 | +4.6% |
| 2024Q4 | E | per share | 2025-03-04 | -0.35 | +0.1% |
| 2024FY | R | per share | 2025-03-04 | -1.72 | +4.6% |
| 2024Q4 | R | per share | 2025-03-04 | -0.35 | +0.1% |
| 2024FY | S | per share | 2025-03-04 | 0.10 | -20.0% |
| 2024Q4 | S | per share | 2025-03-04 | 0.10 | -20.0% |
| 2024Q3 | E | per share | 2024-10-27 | -0.39 | 0.0% |
| 2024Q3 | R | per share | 2024-10-27 | -0.39 | 0.0% |
| 2024Q3 | S | per share | 2024-08-12 | 0.10 | 0.0% |
| 2024Q2 | E | per share | 2024-08-11 | -0.33 | 0.0% |
| 2024Q2 | R | per share | 2024-08-11 | -0.33 | 0.0% |
| 2024Q2 | S | per share | 2024-07-01 | 0.10 | -20.0% |
| 2024Q1 | E | per share | 2024-04-25 | -0.51 | -4.1% |
| 2024Q1 | R | per share | 2024-04-25 | -0.51 | -4.1% |
| 2024Q1 | S | per share | 2024-04-25 | 0.17 | -33.3% |
| 2023FY | E | per share | 2024-01-29 | -2.23 | 0.0% |
| 2023FY | R | per share | 2024-01-29 | -2.23 | 0.0% |
| 2023FY | S | per share | 2024-01-27 | 3.63 | 0.0% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -16.5 | -29.809 | -37.873 | -22.726 | -21.57 | -5.531 | -2.535 | -1.553 | 1.014 | -1.1103 | - |
| Sales USD millions | 1 | 3 | 0 | 10 | 3 | 1 | 4 | 0 | 6 | 39 | - |
| Shares million shares | 2 | 2 | 3 | 4 | 6 | 18 | 27 | 46 | 55 | - | 57 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.63 | -0.204 | -0.242 | 1.706 | -0.095 | -0.372 | -0.302 | -0.354 | -0.083 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 5 | 9 | 11 | 13 |
| Shares million shares | 43 | 46 | 49 | 51 | 52 | 55 | 57 | 57 | 57 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 39.01 | 5.82 | 0.00-100.0% | 3.50+148.2% | 1.41-53.0% | 3.00-70.0% | 10.00 | 0.00-100.0% | 3.00 |
| Cost of Goods Sold Incl. D&A | 18.52 | 5.97+105.2% | 2.91-9.1% | 3.20-30.1% | 4.58+2.7% | 4.46-20.4% | 5.60-35.5% | 8.68 | - |
| Gross Profit | 20.49 | -0.15 | -2.91-1070.0% | 0.30 | -3.16 | -1.46-133.2% | 4.40 | -8.68 | - |
| Selling, General and Administrative Excl. Other | 93.08 | 89.29+45.7% | 61.30+26.4% | 48.50+15.2% | 42.09-24.7% | 55.91+5.7% | 52.90-22.7% | 68.41+16.3% | 58.80 |
| Research and Development | 22.73 | 24.26-29.4% | 34.36+10.5% | 31.09+7.4% | 28.96-15.6% | 34.33+13.9% | 30.14-37.9% | 48.57+25.5% | 38.70 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -72.60 | -89.45 | -64.21 | -48.20 | -45.26 | -57.37 | -48.50 | -77.09 | -58.17 |
| Interest Expense | 2.97 | 3.74-11.2% | 4.21+902.4% | 0.42-43.2% | 0.74-79.8% | 3.67-10.9% | 4.12 | 0.00 | 0.00 |
| Unusual Expense | -6.22 | -6.14-907.9% | 0.76-92.1% | 9.60 | -5.72-123.9% | 23.96-27.2% | 32.92 | - | - |
| Net Income Before Taxes | -62.73 | 71.28 | -63.73 | -54.19 | -39.70 | -84.94 | -84.23 | -76.28 | -56.67 |
| Income Taxes | -0.20 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -62.53 | 71.18 | -63.73 | -54.19 | -39.70 | -84.94 | -84.23 | -76.28 | -56.67 |
| Net Income From Continuing Operations | -62.53 | 71.18 | -63.73 | -54.19 | -39.70 | -84.94 | -84.23 | -76.28 | -56.67 |
| Net Income | -62.53 | 71.18 | -63.73 | -54.19 | -43.48 | -84.94 | -84.23 | -76.28 | -56.67 |
| EPS (Recurring) per share | -1.16 | 0.95 | -1.54 | -2.22 | -6.04 | -17.31 | -16.51 | -37.87 | -29.81 |
| EPS (Basic, Before Extraordinaries) per share | -1.11 | 1.34 | -1.55 | -2.53 | -5.53 | -21.57 | -22.73 | -37.87 | -29.81 |
| EPS (Diluted) per share | -1.11 | 1.01 | -1.55 | -2.53 | -5.53 | -21.57 | -22.73 | -37.87 | -29.81 |
| EBITDA | -68.92 | -85.89 | -61.30 | -45.00 | -40.68 | -52.91 | -42.90 | -68.41 | -55.81 |
| Non-Operating Income (Expense) | 6.61 | 158.33+2810.5% | 5.44+35.0% | 4.03+607.0% | 0.57+714.3% | 0.07-94.6% | 1.30+60.5% | 0.81-46.0% | 1.50 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 9.93 | 8.52+28.5% | 6.63+39.0% | 4.77+56.4% | 3.05-65.8% | 8.92+8.9% | 8.19+11.6% | 7.34-10.3% | 8.18 |
| Price To Sales Ratio ratio | 7.79 | 59.89 | - | 30.60 | 17.12 | 11.06 | 14.55 | - | 113.19 |
| Gross Margin % | 52.51 | -2.65 | - | 8.63 | -223.69 | -48.80 | 43.99 | - | - |
| Operating Margin % | -186.10 | -1,536.91 | - | -1,377.14 | -3,200.64 | -1,912.33 | -485.04 | - | -1,940.16 |
| Net Margin % | -160.30 | 1,223.08 | - | -1,548.23 | -3,074.82 | -2,831.20 | -842.34 | - | -1,890.29 |
| Shares Outstanding million shares | 57.17 | 55.04+20.6% | 45.64+72.1% | 26.52+49.7% | 17.72+200.8% | 5.89+53.0% | 3.85+15.3% | 3.34+74.0% | 1.92 |
| Market Capitalization | 130.87 | 130.87-46.0% | 242.13+95.1% | 124.11+134.6% | 52.90+6.6% | 49.61-67.1% | 150.93-44.8% | 273.44-20.1% | 342.32 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 13.49 | 11.38+2745.0% | 8.72 | 5.42 | 0.00 | 0.40 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 6.42+365.2% | 4.84+456.3% | 3.56+339.5% | 3.70+374.4% | 1.38+91.7% | 0.87-47.9% | 0.81+12.5% | 0.78+8.3% |
| Gross Profit | 7.07 | 6.54 | 5.16 | 1.72 | -1.38 | -0.47 | -0.81 | -0.78 |
| Selling, General and Administrative Excl. Other | 20.07-11.4% | 20.19-9.5% | 28.19+49.1% | 24.63+54.9% | 22.64+54.9% | 22.32+37.8% | 18.91+38.9% | 15.90+27.3% |
| Research and Development | 2.97-17.7% | 4.36-19.3% | 9.55-3.9% | 5.85-34.9% | 3.61-59.6% | 5.40-41.4% | 9.94+37.9% | 8.99+21.8% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -13.00 | -13.65 | -23.03 | -22.91 | -24.02 | -22.79 | -19.73 | -16.67 |
| Interest Expense | 0.56-37.8% | 0.70-27.1% | 0.83-17.0% | 0.88-18.5% | 0.90-18.2% | 0.96-10.3% | 1.00+5.3% | 1.08+881.8% |
| Unusual Expense | -6.51 | 7.19+33.4% | -5.39 | -1.52 | -2.76-118.2% | 5.39 | -7.25-141.9% | -6.78-260.3% |
| Net Income Before Taxes | -4.79 | -20.19-116.2% | -17.07 | -20.68 | -20.36 | 124.34+1578.0% | -12.03 | -9.29 |
| Income Taxes | 0.02 | 0.00-100.0% | 0.00 | -0.21 | -15.20 | 15.51 | 0.00 | 0.00 |
| Consolidated Net Income | -4.81 | -20.19-118.6% | -17.07 | -20.46 | -5.16 | 108.83+1368.7% | -12.03 | -9.29 |
| Net Income From Continuing Operations | -4.81 | -20.19-118.6% | -17.07 | -20.46 | -5.16 | 108.83+1368.7% | -12.03 | -9.29 |
| Net Income | -4.81 | -20.19-118.6% | -17.07 | -20.46 | -5.16 | 108.83+1368.7% | -12.03 | -9.29 |
| EPS (Recurring) per share | -0.16 | -0.27-115.3% | -0.37 | -0.39 | -0.13 | 1.76 | -0.34 | -0.31 |
| EPS (Basic, Before Extraordinaries) per share | -0.08 | -0.35-116.9% | -0.30 | -0.37 | -0.10 | 2.07+989.5% | -0.24 | -0.20 |
| EPS (Diluted) per share | -0.08 | -0.35-120.5% | -0.30 | -0.37 | -0.10 | 1.71 | -0.24 | -0.20 |
| EBITDA | -12.12 | -12.82 | -22.16 | -21.82 | -23.13 | -22.02 | -18.91 | -15.90 |
| Non-Operating Income (Expense) | 2.26+25.6% | 1.35-99.1% | 1.40-3.4% | 1.60-4.8% | 1.80+35.3% | 153.48+10708.5% | 1.45+45.0% | 1.68+75.0% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 2.20+3.8% | 3.37+50.4% | 2.34-13.3% | 2.02+3.1% | 2.12+17.8% | 2.24+69.7% | 2.70+74.2% | 1.96+29.8% |
| Price To Earnings Ratio ratio statement ratio, not the snapshot | - | 6.59 | 4.49 | 4.52 | 8.37 | - | - | - |
| Price To Sales Ratio ratio | 7.79 | 13.82 | 17.45 | 49.84 | 716.00 | 946.30 | - | - |
| Gross Margin % | 52.43 | 57.45 | 59.12 | 31.73 | - | -117.00 | - | - |
| Operating Margin % | -96.37 | -119.97 | -264.14 | -422.71 | - | -5,698.00 | - | - |
| Net Margin % | -35.64 | -177.43 | -195.81 | -377.49 | - | 27,208.25 | - | - |
| Shares Outstanding million shares | 57.17+9.1% | 57.23+11.7% | 56.87+16.2% | 55.04+20.6% | 52.40+20.7% | 51.25+23.0% | 48.95+77.7% | 45.64+72.1% |
| Market Capitalization | 130.87-51.7% | 352.23+21.2% | 255.58+10.6% | 285.59+17.9% | 270.75-1.1% | 290.57+67.3% | 231.02+16.5% | 242.13+95.1% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 191.40+95.2% | 98.06+86.6% | 52.56+0.1% | 52.49+4.9% | 50.02-47.4% | 95.03-26.5% | 129.26+52.1% | 84.97-38.3% | 137.75 |
| Short Term Receivables | 6.71+306.7% | 1.65-32.4% | 2.44+1184.2% | 0.19-93.7% | 3.00 | 0.00 | 0.00-100.0% | 0.08-27.3% | 0.11 |
| Inventories | 5.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.29+13.2% | 1.14+56.2% | 0.73+73.8% | 0.42-82.4% | 2.39-11.8% | 2.71-13.4% | 3.13-17.6% | 3.80+39.2% | 2.73 |
| Total Current Assets | 204.91+103.2% | 100.85+80.9% | 55.74+5.0% | 53.10-4.2% | 55.40-43.3% | 97.74-26.2% | 132.39+49.0% | 88.85-36.8% | 140.59 |
| Net Property, Plant & Equipment | 13.88+73.9% | 7.98-0.1% | 7.99-27.8% | 11.07-49.1% | 21.74+18.5% | 18.35-13.4% | 21.20+124.6% | 9.44+589.1% | 1.37 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.90-7.2% | 0.97-12.6% | 1.11+98.2% | 0.56 | 0.00 |
| Intangible Assets | - | - | 0.00 | 0.00-100.0% | 1.38-95.9% | 33.97-50.5% | 68.64-9.1% | 75.51+107.2% | 36.44 |
| Deferred Tax Assets | 1.60 | - | - | - | - | - | - | - | - |
| Other Assets | 0.78+680.0% | 0.10-64.3% | 0.28+600.0% | 0.04-75.0% | 0.160.0% | 0.16+433.3% | 0.03-25.0% | 0.04-88.9% | 0.36 |
| Total Assets | 221.17+103.0% | 108.93+70.2% | 64.00-0.3% | 64.21-19.3% | 79.59-47.4% | 151.20-32.3% | 223.38+28.1% | 174.40-2.4% | 178.77 |
| Short Term Debt Incl. Current Port. of LT Debt | 13.09+93.9% | 6.75+575.0% | 1.00-43.5% | 1.77-2.7% | 1.82-10.8% | 2.04+20.0% | 1.70 | 0.00 | 0.00 |
| Accounts Payable | 7.89+129.4% | 3.44+84.9% | 1.86+2.8% | 1.81-58.2% | 4.33-7.9% | 4.70+25.0% | 3.76-38.6% | 6.12+156.1% | 2.39 |
| Income Tax Payable | 0.13 | - | - | - | - | - | - | - | - |
| Other Current Liabilities | 8.47+32.3% | 6.40-39.5% | 10.57+151.7% | 4.20-59.9% | 10.48-70.2% | 35.22+6.0% | 33.24+133.6% | 14.23+343.3% | 3.21 |
| Total Current Liabilities | 29.57+78.2% | 16.59+23.6% | 13.42+72.5% | 7.78-53.2% | 16.62-60.4% | 41.96+8.4% | 38.70+90.2% | 20.35+262.7% | 5.61 |
| Long Term Debt | 11.88-27.1% | 16.30+270.5% | 4.40-24.8% | 5.85-22.6% | 7.56+13.0% | 6.69+7.0% | 6.25 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 1.60 | - | - | - | - | - | - | - | - |
| Other Liabilities | 18.90-41.0% | 32.01+2.1% | 31.35+31.6% | 23.82+491.1% | 4.03 | 0.00 | 0.00-100.0% | 20.00+553.6% | 3.06 |
| Total Liabilities | 61.96-4.5% | 64.90+32.0% | 49.18+31.3% | 37.45+32.8% | 28.21-42.0% | 48.65+8.2% | 44.95+11.4% | 40.35+365.4% | 8.67 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 159.22+261.6% | 44.03+196.9% | 14.83-44.6% | 26.76-47.9% | 51.38-49.9% | 102.55-42.5% | 178.43+33.1% | 134.04-21.2% | 170.10 |
| Total Shareholders Equity | 159.22+261.6% | 44.03+196.9% | 14.83-44.6% | 26.76-47.9% | 51.38-49.9% | 102.55-42.5% | 178.43+33.1% | 134.04-21.2% | 170.10 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 159.22+261.6% | 44.03+196.9% | 14.83-44.6% | 26.76-47.9% | 51.38-49.9% | 102.55-42.5% | 178.43+33.1% | 134.04-21.2% | 170.10 |
| Total Liabilities & Stockholders Equity | 221.17+103.0% | 108.93+70.2% | 64.00-0.3% | 64.21-19.3% | 79.59-47.4% | 151.20-32.3% | 223.38+28.1% | 174.40-2.4% | 178.77 |
| Book Value Per Share per share | 2.89+201.0% | 0.96+71.4% | 0.56-62.9% | 1.51-82.7% | 8.73-67.3% | 26.67-50.0% | 53.34-23.7% | 69.90-22.9% | 90.69 |
| Tangible Book Value Per Share per share | 2.89+201.0% | 0.96+71.4% | 0.56-62.9% | 1.51-82.2% | 8.49-52.4% | 17.84-45.6% | 32.82+7.5% | 30.52-57.2% | 71.26 |
| Full-Time Employees people | 226+66.2% | 136+61.9% | 84+47.4% | 57-36.7% | 90+18.4% | 76-13.6% | 88+6.0% | 83+97.6% | 42 |
| Price to Book Ratio ratio | 1.04 | 5.28 | 5.62 | 1.53 | 0.97 | 1.47 | 1.53 | 2.28 | 7.22 |
| Return on Assets % | 43.13 | -73.71 | -84.53 | -55.21 | -73.61 | -44.98 | -38.35 | -32.09 | -18.85 |
| Return on Equity % | 70.05 | -216.57 | -260.60 | -101.61 | -110.36 | -59.96 | -48.82 | -37.27 | -20.30 |
| Return on Invested Capital % | 41.60 | -105.64 | -281.82 | -121.71 | -144.12 | -77.11 | -41.30 | -42.28 | -16.06 |
| Quick Ratio ratio | 6.74 | 6.08 | 4.15 | 6.83 | 3.33 | 2.33 | 3.42 | 4.37 | 25.07 |
| Current Ratio ratio | 6.93 | 6.08 | 4.15 | 6.83 | 3.33 | 2.33 | 3.42 | 4.37 | 25.07 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -62.53 | 71.18 | -63.73 | -54.19 | -39.70 | -84.94 | -84.23 | -76.28 | -56.67 |
| Depreciation | 3.67 | 3.56+22.3% | 2.91-9.1% | 3.20-30.1% | 4.58+2.7% | 4.46-20.4% | 5.60-35.5% | 8.68+267.8% | 2.36 |
| Other Funds (Non Cash) | 7.07 | -145.69-1683.6% | 9.20-41.1% | 15.62 | -2.47-107.5% | 33.07-21.2% | 41.98+403.4% | 8.34+1.2% | 8.24 |
| Funds from Operations | -51.79 | -70.94 | -51.63 | -35.37 | -37.59 | -47.40 | -36.65 | -59.27 | -46.07 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -11.77 | -5.39 | -4.38 | -1.79 | -5.89 | -18.26-1220.2% | 1.63 | -3.55-151.0% | 6.96 |
| Income Taxes Payable | -0.31 | 0.13 | - | - | - | - | - | - | - |
| Cash from Operating Activities | -63.56 | -76.33 | -56.02 | -37.16 | -43.48 | -65.67 | -35.02 | -62.82 | -39.11 |
| Capital Expenditures | -2.79 | -7.97 | -2.45 | -0.33 | -0.13 | -4.15 | -1.34 | -6.51 | -19.49 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00-100.0% | 0.02-90.0% | 0.20-88.4% | 1.73 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | 54.69 | -39.36 | -36.81-11254.5% | 0.33 | -25.57-136.4% | 70.21 | -82.38-223.9% | 66.48 | -65.59 |
| Purchase of Investments | -109.58 | -206.63 | -157.01 | -51.64 | -78.21 | -20.16 | -170.47 | 0.00 | -136.09 |
| Sale Or Maturity of Investments | 164.28 | 167.27+39.2% | 120.20+131.3% | 51.97-1.3% | 52.64-41.8% | 90.38+2.6% | 88.09+32.5% | 66.48-5.7% | 70.50 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 152.37 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Cash from Investing Activities | 51.91 | 105.03 | -39.24-18785.7% | 0.21 | -23.96-136.3% | 66.06 | -83.71-239.6% | 59.98 | -85.09 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 3.61 | 26.08-69.5% | 85.63+130.1% | 37.21-13.8% | 43.17+73.7% | 24.86+13711.1% | 0.18-99.8% | 113.90+1978.5% | 5.48 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 3.61 | 26.08-69.5% | 85.63+130.1% | 37.21-13.8% | 43.17+73.7% | 24.86+13711.1% | 0.18-99.8% | 113.90+1978.5% | 5.48 |
| Proceedsfrom Stock Options | 0.00 | 17.30-79.9% | 86.15+130.4% | 37.39-13.4% | 43.18+79.7% | 24.03 | 0.00-100.0% | 16.96 | 0.00 |
| Issuance or Reduction of Debt, Net | -8.89 | 0.00-100.0% | 19.04 | 0.00 | 0.00 | 0.00-100.0% | 1.76 | 0.00 | 0.00 |
| Change in Long Term Debt | -8.89 | 0.00-100.0% | 19.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00-100.0% | 19.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -8.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.01 | -0.04 | -0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -0.01 | -0.04 | -0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -5.29 | 26.04-75.0% | 104.14+179.9% | 37.21-13.8% | 43.17+73.7% | 24.86+1181.4% | 1.94-98.3% | 113.90+1978.5% | 5.48 |
| Net Change in Cash | -16.94 | 54.74+516.4% | 8.88+3315.4% | 0.26 | -24.27-196.1% | 25.26 | -116.80-205.2% | 111.06 | -118.72 |
| Free Cash Flow | -66.35 | -84.30 | -58.46 | -37.49 | -43.61 | -69.82 | -36.35 | -69.13 | -48.35 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 134.94-35.0% | 146.83-35.0% | 168.27+99.2% | 191.40+95.2% | 207.46+88.5% | 225.86+83.6% | 84.49+34.8% | 98.06+86.6% |
| Short Term Receivables | 16.21+900.6% | 9.89+506.7% | 6.71+314.2% | 6.71+306.7% | 1.62+0.6% | 1.63-0.6% | 1.62-27.4% | 1.65-32.4% |
| Inventories | 4.66-3.9% | 5.92+120.1% | 6.05 | 5.49 | 4.85 | 2.69 | 0.00 | 0.00 |
| Other Current Assets | 1.90-14.0% | 1.94-7.2% | 1.95-3.0% | 1.29+13.2% | 2.21+121.0% | 2.09+71.3% | 2.01+11.0% | 1.14+56.2% |
| Total Current Assets | 157.72-27.0% | 164.58-29.1% | 182.99+107.7% | 204.91+103.2% | 216.13+91.8% | 232.26+84.5% | 88.12+32.1% | 100.85+80.9% |
| Net Property, Plant & Equipment | 13.38-7.2% | 14.10+3.4% | 14.68+31.2% | 13.88+73.9% | 14.42+83.7% | 13.63+70.4% | 11.19+40.1% | 7.98-0.1% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Assets | - | - | - | 1.60 | - | - | - | - |
| Other Assets | 0.83+53.7% | 0.83+144.1% | 0.83+1283.3% | 0.78+680.0% | 0.54+500.0% | 0.34+240.0% | 0.06-45.5% | 0.10-64.3% |
| Total Assets | 171.92-25.6% | 179.51-27.1% | 198.49+99.8% | 221.17+103.0% | 231.09+91.6% | 246.23+83.8% | 99.36+32.8% | 108.93+70.2% |
| Short Term Debt Incl. Current Port. of LT Debt | 13.16+46.4% | 14.61+139.9% | 14.61+66.8% | 13.09+93.9% | 8.99+63.5% | 6.09+51.9% | 8.76+742.3% | 6.75+575.0% |
| Accounts Payable | 3.41-42.5% | 2.99-59.3% | 4.07-18.9% | 7.89+129.4% | 5.93+112.5% | 7.34+136.8% | 5.02+49.4% | 3.44+84.9% |
| Income Tax Payable | - | - | 0.00 | 0.13 | 0.34 | 15.51 | - | - |
| Other Current Liabilities | 11.13+60.8% | 7.20+29.0% | 12.37+194.5% | 8.47+32.3% | 6.92-31.7% | 5.58-42.7% | 4.20-43.9% | 6.40-39.5% |
| Total Current Liabilities | 27.71+24.9% | 24.81-28.1% | 31.05+72.7% | 29.57+78.2% | 22.18+20.4% | 34.52+105.0% | 17.98+51.2% | 16.59+23.6% |
| Long Term Debt | 3.46-77.1% | 5.26-70.7% | 8.57-43.7% | 11.88-27.1% | 15.12-14.1% | 17.98-6.1% | 15.22-31.2% | 16.30+270.5% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 1.60 | - | - | - | - |
| Other Liabilities | 14.88-34.1% | 21.38-29.1% | 13.94-43.7% | 18.90-41.0% | 22.57-41.8% | 30.16+21.8% | 24.77-50.2% | 32.01+2.1% |
| Total Liabilities | 46.05-23.1% | 51.45-37.8% | 53.55-7.6% | 61.96-4.5% | 59.86-20.0% | 82.66+36.0% | 57.97-30.7% | 64.90+32.0% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 125.88-26.5% | 128.06-21.7% | 144.94+250.1% | 159.22+261.6% | 171.23+274.1% | 163.58+123.3% | 41.40 | 44.03+196.9% |
| Total Shareholders Equity | 125.88-26.5% | 128.06-21.7% | 144.94+250.1% | 159.22+261.6% | 171.23+274.1% | 163.58+123.3% | 41.40 | 44.03+196.9% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 125.88-26.5% | 128.06-21.7% | 144.94+250.1% | 159.22+261.6% | 171.23+274.1% | 163.58+123.3% | 41.40 | 44.03+196.9% |
| Total Liabilities & Stockholders Equity | 171.92-25.6% | 179.51-27.1% | 198.49+99.8% | 221.17+103.0% | 231.09+91.6% | 246.23+83.8% | 99.36+32.8% | 108.93+70.2% |
| Book Value Per Share per share | 2.20-32.7% | 2.24-29.8% | 2.55+200.0% | 2.89+201.0% | 3.27+211.4% | 3.19+81.3% | 0.85 | 0.96+71.4% |
| Tangible Book Value Per Share per share | 2.20-32.7% | 2.24-29.8% | 2.55+200.0% | 2.89+201.0% | 3.27+211.4% | 3.19+81.3% | 0.85 | 0.96+71.4% |
| Full-Time Employees people | - | - | - | 226+66.2% | - | - | - | 136+61.9% |
| Price to Book Ratio ratio | 1.04 | 2.42 | 1.55 | 1.61 | 1.65 | 6.72 | 4.93 | 5.28 |
| Return on Assets % | -31.03 | -29.54 | 44.41 | 43.13 | 46.83 | 30.11 | -50.73 | -73.71 |
| Return on Equity % | -42.09 | -43.13 | 70.99 | 70.05 | 75.90 | 48.34 | -271.78 | -216.57 |
| Return on Invested Capital % | -3.72 | -15.15 | -11.12 | -11.96 | -2.77 | 59.94 | -21.25 | -15.40 |
| Quick Ratio ratio | 5.52 | 6.40 | 5.70 | 6.74 | 9.53 | 6.65 | 4.90 | 6.08 |
| Current Ratio ratio | 5.69 | 6.63 | 5.89 | 6.93 | 9.74 | 6.73 | 4.90 | 6.08 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -4.81 | -20.19-118.6% | -17.07 | -20.46 | -5.16 | 108.83+1368.7% | -12.03 | -9.29 |
| Depreciation | 0.88-1.1% | 0.83+7.8% | 0.87+7.4% | 1.09+39.7% | 0.89+23.6% | 0.77+11.6% | 0.81+12.5% | 0.78+8.3% |
| Other Funds (Non Cash) | -3.67-3436.4% | 10.87 | -2.14 | 2.01 | 0.11-99.4% | -144.04 | -3.77-119.7% | -4.21-177.0% |
| Funds from Operations | -7.59 | -8.49 | -18.35 | -17.36 | -4.16 | -34.44 | -14.98 | -12.72 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.71 | -9.01-157.6% | -1.46 | -0.59 | -17.02 | 15.65+538.8% | -3.42 | -3.84-480.2% |
| Income Taxes Payable | 0.03 | 0.00 | -0.13 | -0.21 | -15.17 | - | - | - |
| Cash from Operating Activities | -8.31 | -17.50 | -19.80 | -17.95 | -21.19 | -18.78 | -18.40 | -16.56 |
| Capital Expenditures | -0.22 | -0.48 | -0.94 | -1.15 | -2.52 | -2.90 | -1.40 | -0.61 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | 0.00-100.0% |
| Purchase or Sale of Investments | 21.92 | 16.16+151.7% | 5.90+5.2% | 10.71-45.0% | -62.11 | 6.42 | 5.61 | 19.48+68.7% |
| Purchase of Investments | -28.09 | -24.71 | -19.00 | -37.78 | -100.35 | -19.85 | -48.65 | -10.48 |
| Sale Or Maturity of Investments | 50.02+30.8% | 40.87+55.5% | 24.90-54.1% | 48.49+61.8% | 38.24-24.8% | 26.28+53.6% | 54.26+143.9% | 29.96+100.1% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00-100.0% | 0.00 | 0.00 | 0.00 | 152.37 | 0.00 | 0.00 |
| Cash from Investing Activities | 21.70 | 15.69-89.9% | 4.96+17.8% | 9.55-49.4% | -64.63 | 155.89 | 4.21 | 18.88+63.7% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 3.61-34.5% | 5.16 | 10.50-85.8% | 6.80+5.9% | 5.51-27.5% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 3.61-34.5% | 5.16 | 10.50-85.8% | 6.80+5.9% | 5.51-27.5% |
| Proceedsfrom Stock Options | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00 | 10.50-85.8% | 6.80+5.9% | 6.04-22.5% |
| Issuance or Reduction of Debt, Net | -3.33 | -3.33 | -2.22 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 |
| Change in Long Term Debt | -3.33 | -3.33 | -2.22 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 |
| Reduction of Long Term Debt | -3.33 | -3.33 | -2.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.01 | -0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.03 | -0.20-2100.0% |
| Other Financing Activities Uses | -0.01 | -0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.03 | -0.20-2100.0% |
| Cash from Financing Activities | -3.34-164.7% | -3.33-131.7% | -2.22-132.8% | 3.61-32.0% | 5.16 | 10.49-85.8% | 6.77-73.4% | 5.31-30.3% |
| Net Change in Cash | 10.05 | -5.14-103.5% | -17.06 | -4.79-162.8% | -80.65 | 147.60+774.9% | -7.42-340.9% | 7.63-21.8% |
| Free Cash Flow | -8.53 | -17.98 | -20.74 | -19.11 | -23.71 | -21.68 | -19.80 | -17.16 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2025 | 2025 share |
|---|---|---|
| License | 3.40 | 58.4% |
| Product | 2.42 | 41.6% |
| Total | 5.82 | 100.0% |
| Name | 2025 | 2025 share |
|---|---|---|
| United States | 5.82 | 100.0% |
| Total | 5.82 | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 33.29% | 16.9M | 50.7M | 1.34M |
| 2026-10-15 | 33.95% | 17.2M | 50.7M | 1.40M |
| 2026-09-30 | 33.30% | 16.9M | 50.7M | 1.44M |
| 2026-09-15 | 31.08% | 15.7M | 50.7M | 1.46M |
| 2026-08-31 | 29.93% | 15.2M | 50.6M | 1.38M |
| 2026-08-14 | 28.24% | 14.3M | 50.5M | 1.36M |
| 2026-07-31 | 27.07% | 13.6M | 50.4M | 1.25M |
| 2026-07-15 | 26.26% | 13.2M | 50.4M | 1.19M |
| 2026-06-30 | 27.21% | 13.7M | 50.3M | 1.13M |
| 2026-06-15 | 28.13% | 14.1M | 50.3M | 1.15M |
| 2026-05-29 | 28.72% | 14.4M | 50.1M | 1.23M |
| 2026-05-15 | 28.87% | 14.5M | 50.1M | 1.23M |
| 2026-04-30 | 34.12% | 16.5M | 48.3M | 1.15M |
| 2026-04-15 | 34.09% | 16.5M | 48.3M | 1.27M |
| 2026-03-31 | 31.09% | 15.8M | 51.0M | 1.26M |
| 2026-03-13 | 29.63% | 15.1M | 51.0M | 1.14M |
| 2026-02-27 | 26.96% | 13.1M | 48.4M | 1.13M |
| 2026-02-13 | 28.27% | 13.7M | 48.4M | 1.28M |
| 2026-01-30 | 29.48% | 14.3M | 48.6M | 1.72M |
| 2026-01-15 | 28.21% | 13.8M | 49.0M | 1.72M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 1.00 | 0.00 | 4.90 | 3.56 | 0.000 | 2.00 | 0.00 | 0.942 | -0.011 | 0.000 |
| call | 2.00 | 0.00 | 4.90 | 0.80 | 0.000 | 12.00 | 0.00 | 0.721 | -0.016 | 0.001 |
| call | 3.00 | 0.00 | 4.90 | 0.05 | 0.000 | 51.00 | 0.00 | 0.538 | -0.049 | 0.001 |
| call | 4.00 | 0.00 | 4.90 | 0.05 | 0.000 | 62.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 5.00 | 0.00 | 0.05 | 0.03 | 3.327 | 651 | 0.00 | 0.107 | -0.012 | 0.001 |
| call | 6.00 | 0.00 | 0.05 | 0.05 | 3.855 | 93.00 | 0.00 | 0.097 | -0.013 | 0.001 |
| call | 7.00 | 0.00 | 4.90 | 0.05 | 4.512 | 47.00 | 0.00 | 0.090 | -0.015 | 0.001 |
| call | 8.00 | 0.00 | 4.90 | 0.00 | 4.850 | 0.00 | 0.00 | 0.086 | -0.016 | 0.001 |
| call | 9.00 | 0.00 | 4.90 | 0.00 | 5.168 | 0.00 | 0.00 | 0.082 | -0.016 | 0.001 |
| call | 10.00 | 0.00 | 4.90 | 0.00 | 5.446 | 0.00 | 0.00 | 0.079 | -0.017 | 0.001 |
| call | 11.00 | 0.00 | 4.90 | 0.00 | 5.692 | 0.00 | 0.00 | 0.077 | -0.017 | 0.000 |
| put | 1.00 | 0.00 | 0.05 | 0.00 | 4.558 | 0.00 | 0.00 | -0.058 | -0.011 | 0.000 |
| put | 2.00 | 0.00 | 0.15 | 0.00 | 2.078 | 0.00 | 0.00 | -0.275 | -0.014 | 0.001 |
| put | 3.00 | 0.50 | 1.25 | 0.70 | 5.695 | 21.00 | 2.00 | -0.462 | -0.048 | 0.001 |
| put | 4.00 | 0.00 | 4.90 | 1.00 | 0.000 | 15.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| put | 5.00 | 0.10 | 4.90 | 0.62 | 29.877 | 3.00 | 0.00 | -0.893 | -0.013 | 0.001 |
| put | 6.00 | 1.25 | 6.00 | 2.47 | 0.000 | 0.00 | 0.00 | -0.903 | -0.014 | 0.001 |
| put | 7.00 | 2.20 | 7.00 | 0.00 | 0.000 | 0.00 | 0.00 | -0.910 | -0.015 | 0.001 |
| put | 8.00 | 3.60 | 8.00 | 0.00 | 0.000 | 0.00 | 0.00 | -0.914 | -0.016 | 0.001 |
| put | 9.00 | 4.10 | 9.00 | 0.00 | 0.000 | 0.00 | 0.00 | -0.918 | -0.016 | 0.001 |
| put | 10.00 | 5.10 | 10.00 | 0.00 | 0.000 | 0.00 | 0.00 | -0.921 | -0.016 | 0.000 |
| put | 11.00 | 6.20 | 10.80 | 0.00 | 28.025 | 0.00 | 0.00 | -0.923 | -0.017 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | SCHEDULE 13G/A | SEC | ||
| 2026-11-09 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-09 | 8-K | Current report | 2026-11-09 | SEC |
| 2026-11-09 | 8-K | Current report | 2026-11-06 | SEC |
| 2026-10-23 | SCHEDULE 13D | SEC | ||
| 2026-09-29 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-29 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-29 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-29 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-29 | SEC |
| 2026-09-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-29 | SEC |
| 2026-09-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-29 | SEC |
| 2026-09-29 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-29 | SEC |
| 2026-09-15 | 8-K | Current report | 2026-09-15 | SEC |
| 2026-09-01 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-01 | SEC |
| 2026-08-14 | SCHEDULE 13G/A | SEC | ||
| 2026-08-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-21 | SEC |
| 2026-07-10 | 424B3 | SEC | ||
| 2026-07-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-09 | SEC |
| 2026-07-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-09 | SEC |
| 2026-07-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-09 | SEC |
| 2026-07-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-09 | SEC |
| 2026-07-06 | 144 | Filing for proposed sale of securities under Rule 144. | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 296.40K | 5 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 827.93K | 5 |
| 2026-06 | 0 | 0 | 847.14K | 10 |
| 2026-05 | 0 | 0 | 213.17K | 3 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 135.22K | 2 |
| 2026-02 | 0 | 0 | 362.62K | 5 |
| 2026-01 | 0 | 0 | 681.39K | 5 |
| 2025-12 | 0 | 0 | 132.74K | 1 |
| 2025-11 | 0 | 0 | 71.17K | 1 |
Institutional holders
| Manager | % owned |
|---|---|
| Nantahala Capital Management, LLC | 18.02% |
| BlackRock, Inc. | 5.88% |
| Cable Car Capital, LP | 5.28% |
| AIGH Capital Management LLC | 5.07% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.88% |
| OneDigital Investment Advisors LLC | 2.90% |
| AWM Investment Company, Inc. | 2.61% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.32% |
| KENNEDY CAPITAL MANAGEMENT LLC | 2.18% |
| GOLDMAN SACHS GROUP INC | 2.15% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.68% |
| iShares Russell 2000 ETF | 2.08% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.10% |
| Fidelity Small Cap Index Fund | 0.84% |
| iShares Russell 2000 Value ETF | 0.72% |
| Simplify Propel Opportunities ETF | 0.61% |
| Fidelity Extended Market Index Fund | 0.48% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.44% |
| iShares Micro-Cap ETF | 0.25% |
| Fidelity Enhanced Small Cap Core ETF | 0.23% |
OakChart. ABEO. Cached 15 minutes. Terms